

Unknown

**From:** Lloyd (Washington) Lisa M  
**Sent:** Tuesday, September 10, 2002 11:30 AM  
**To:** Beamish, Don G  
**Subject:** RE: URGENT ACTION - Trial 41 dissemination

Don,

Just a head's up - Ann mentioned that many of our advisors were Trial 41 investigators - Schulz, Nasrallah to name a few. She will send me the list of investigators before our meeting.

Also, I would like to talk to you about the contingency planning meeting driven by global. Rebecca mentioned that we could add some USPT members and I would like to talk to you about that.

*Lisa Lloyd-Washington*  
Brand Director, SEROQUEL  
302-886-7875  
lisa.lloyd@astrazeneca.com

-----Original Message-----

**From:** Beamish, Don G  
**Sent:** Monday, September 09, 2002 4:21 PM  
**To:** Ault, Brian; Bullinger, Ann; Eash, James; Goldstein, Jeffrey M; Jensen, Kimberly A; Limp, Gerald L; Lloyd (Washington) Lisa M; Mullen, Jamie A; Paulson, Alfred N; Rocheleau, Jay O; Stebbins, Enid  
**Subject:** FW: URGENT ACTION - Trial 41 dissemination  
**Importance:** High

FYI and action if appropriate

-----Original Message-----

**From:** Hagger, Simon  
**Sent:** Monday, September 09, 2002 3:19 PM  
**To:** Melville, Margaret G; McCormack, Eileen; Sepelyak, Robert J; French, Scott B; Schwartz, Jack A; Bailey, Jill C; Christopher, Eric S; Sheridan, Louise PL; Lloyd (Washington) Lisa M; Beamish, Don G; McCormack, Eileen; Stirling, Grant  
**Cc:** Oldham, Alex; Fitton, Lesley R; Bowen, Rebecca; Street, Paul R  
**Subject:** URGENT ACTION - Trial 41 dissemination  
**Importance:** High

Dear colleagues,


The SR Communications Team met earlier today to discuss the process for disseminating information to external colleagues who have been involved in the SR program. You will all be aware that we are under clear instruction from the highest level within AstraZeneca at this time not to discuss details surrounding trial 41 with any external customers. Infact any internal discussion around trial 41 should remain limited until we have a clearer interpretation of the data and have established the way forward with both the SR and IR programs. A full communication plan is currently being developed and will include details of how and when any information is shared with our agencies and other external partners. We will share this plan with you in due course but, in the meantime, we urgently need to know from you the names of any external partners you have worked with on the SR program and you feel, in the course of their continuing work, will need to know more details. The same message remains until further notice that until analysis of all the data supporting the SR program is complete, there is no further information available. Formal communication timelines will be provided detailing our next steps in this process. In the meantime **please complete, by return, the attached table** with the names, contact details of any external SR partners (and the nature of their involvement in the SR program) that would necessitate formal contact.

<< File: Trial 41 external partners listing.xls >>

Please do not hesitate to contact Rebecca Bowen, Alex Oldham or myself if you have any questions.

Regards,  
**Simon**

Simon Hagger



Global Brand Manager, Seroquel  
PS&L  
AstraZeneca Pharmaceuticals, US  
Tel: 302 885 1089  
Fax: 302 886 8010  
Mobile: **REDACTED**  
simon.hagger@astrazeneca.com